- Home
- PRME vs CEPF Comparison
PRME vs CEPF Comparison
Compare PRME & CEPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.34
Company Overview
Basic Information| Metric | PRME | CEPF |
|---|---|---|
| Founded | 2019 | 2021 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 666.1M | 590.9M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRME | CEPF |
|---|---|---|
| Price | $3.34 | $10.43 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.42 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 174.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,983,000.00 | N/A |
| Revenue This Year | $95.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $96.45 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $10.09 |
| 52 Week High | $6.94 | $10.67 |
Technical Indicators
Market Signals| Indicator | PRME | CEPF |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 51.86 |
| Support Level | $3.16 | $10.37 |
| Resistance Level | $3.39 | $10.47 |
| Average True Range (ATR) | 0.27 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 17.06 | 50.00 |
Price Performance
Historical Comparison PRME
CEPF
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.